Chong Kun Dang Pharmaceutical: Dyslipidemias trials

The registry lists 39 Dyslipidemias studies with Chong Kun Dang Pharmaceutical as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 34Phase 2 1Phase 3 3Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Study to Evaluate Drug-drug Interaction and Safety After Co-administration of D352 and D794 in Healthy Adult VolunteersCompletedNCT06758661Phase 1
• A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6)CompletedNCT06112678Phase 1
• A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2)CompletedNCT06088017Phase 1
• A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)CompletedNCT05749861Phase 1
• A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mgCompletedNCT05698043Phase 1
• A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391CompletedNCT05634447Phase 1
• Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting ConditionsCompletedNCT05552495Phase 1
• Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348CompletedNCT05549401Phase 1
• Study to Evaluate the Safety and Pharmacokinetics of CKD-331CompletedNCT05335044Phase 1
• A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mgCompletedNCT05245084Phase 1
• A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)CompletedNCT05192356Phase 1
• A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mgCompletedNCT04987970Phase 1
• A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2)CompletedNCT04883658Phase 1
• A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)CompletedNCT04694989Phase 1
• A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386CompletedNCT04673864Phase 1
• A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348CompletedNCT04660370Phase 1
• A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348CompletedNCT04587206Phase 1
• Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) TabletStatus unknownNCT04388215Phase 3
• Clinical Trial to Evaluate the Efficacy and Safety of CKD-386CompletedNCT04312698Phase 3
• A Clinical Trial to Compare the Pharmacokinetics and Tolerability of CKD-348CompletedNCT04258865Phase 1
• Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy VolunteersCompletedNCT04019743Phase 1
• A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Male VolunteersStatus unknownNCT03920579Phase 1
• Compare the Pharmacokinetics and Safety of CKD-333 With Co-administration CKD-330 and D090 in Healthy Male AdultsStatus unknownNCT03849287Phase 1
• A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy SubjectsStatus unknownNCT03726866Phase 1
• Pharmacokinetics and Safety Profile of CKD-333CompletedNCT03659149Phase 1
• A Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male SubjectsCompletedNCT03609606Phase 1
• Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 TabletCompletedNCT03583905Phase 3
• A Clinical Trial to Assess the Effects of Food on the Bioavailability of CKD-337CompletedNCT03382756Phase 1
• A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337CompletedNCT03346187Phase 1
• Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519CompletedNCT03210649Phase 1
• Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male SubjectsCompletedNCT03175835Phase 1
• To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase InhibitorsCompletedNCT02977065Phase 2
• Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519CompletedNCT02753504Phase 1
• A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337CompletedNCT02651753Phase 1
• Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject.CompletedNCT02623868Phase 1
• Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519(CKD-519 FDI)CompletedNCT02484482Phase 1
• Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519CompletedNCT02156544Phase 1
• CKD-337 Drug Interaction StudyCompletedNCT02066207Phase 1
• Dyslipidemia in Cardiovascular DiseaseCompletedNCT01029522Phase 4